StreetInsider.com News Articles

Form PREM14A Lantheus Holdings, Inc. For: Aug 26

Wed, 26 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26977279.html

Form PREM14A Lantheus Holdings, Inc. For: Aug 26

Wed, 26 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26977279.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Brown Kimberly

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950571.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Brown Kimberly

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950571.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Dinkelborg Ludger

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950574.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Dinkelborg Ludger

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950574.html

B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral

Mon, 17 Aug 2026 12:16:40 -0400

B.Riley analyst Justin Walsh downgraded Lantheus Holdings (NASDAQ: LNTH) from Buy to Neutral with a price target of $105.40 (from $129.00).

The analyst comments "Curium will acquire Lantheus Holdings, Inc. (LNTH — Buy, $105.40 PT) for $102.50/sh plus up to $12/sh in CVRs for 2030 milestones, with a closing in 1H27, against a May 2, 2027, outside date. We believe three overlaps exist: 1) Detectnet (Curium) vs. OCTEVY in NET imaging; 2) Cu64- PSMA-I&T (Curium) vs. Pylarify TruVu, and 3) Lu177 dotatate vs. PNT2003, both of which are generic versions of Lutathera. According to the AGREEMENT AND PLAN OF MERGER, Curium

B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral

Mon, 17 Aug 2026 12:16:40 -0400

B.Riley analyst Justin Walsh downgraded Lantheus Holdings (NASDAQ: LNTH) from Buy to Neutral with a price target of $105.40 (from $129.00).

FDA approves Lantheus tau PET imaging agent for Alzheimer's disease

Fri, 14 Aug 2026 08:00:31 -0400

Lantheus Holdings (NASDAQ: LNTH) announced that the U.S. Food and Drug Administration has approved TAUKLARIFY (florquinitau F 18 injection), a radiodiagnostic agent for positron emission tomography imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer's disease.

The agent, also referred to as MK-6240, is indicated to identify patients with tau neurofibrillary tangle pathology. The FDA has noted a limitation of use: the safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer's disease tauopathies.

The approval is supported by two blinded read studies analyzing PET images from more than 500 subjects across three clinical

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

Fri, 14 Aug 2026 08:00:00 -0400

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle (NFT) pathology. TAUKLARIFY has a limitation of use. The safety and

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

Fri, 14 Aug 2026 08:00:00 -0400

Form DEFA14A Lantheus Holdings, Inc.

Thu, 13 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26922792.html

Form DEFA14A Lantheus Holdings, Inc.

Thu, 13 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26922792.html

Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26922738.html

Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26922738.html

Form 10-Q Lantheus Holdings, Inc. For: Jun 30

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879293.html

Form 10-Q Lantheus Holdings, Inc. For: Jun 30

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879293.html

Lantheus Holdings (LNTH) Tops Q2 EPS by 26c

Thu, 06 Aug 2026 07:52:24 -0400

Lantheus Holdings (NASDAQ: LNTH) reported Q2 EPS of $1.55, $0.26 better than the analyst estimate of $1.29. Revenue for the quarter came in at $388.2 million versus the consensus estimate of $362.32 million.

For earnings history and earnings-related data on Lantheus Holdings (LNTH) click here.

Form 8-K Lantheus Holdings, Inc. For: Aug 06

Thu, 06 Aug 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260806/26878965.html

Form 8-K Lantheus Holdings, Inc. For: Aug 06

Thu, 06 Aug 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260806/26878965.html

Lantheus Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Worldwide revenue of $388.2 million in the second quarter of 2026
GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025
Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025
Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion

BEDFORD, Mass.,

Lantheus Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Worldwide revenue of $388.2 million in the second quarter of 2026
GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025
Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025
Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion

BEDFORD, Mass.,

Form DEFA14A Lantheus Holdings, Inc.

Tue, 04 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260804/26866755.html

Form DEFA14A Lantheus Holdings, Inc.

Tue, 04 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260804/26866755.html

CJS Securities Downgrades Lantheus Holdings (LNTH) to Market Perform

Tue, 04 Aug 2026 08:30:55 -0400

CJS Securities analyst Larry Solow downgraded Lantheus Holdings (NASDAQ: LNTH) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Lantheus Holdings click here. For more ratings news on Lantheus Holdings click here.

Shares of Lantheus Holdings closed at $101.19 yesterday.